Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-08-16 | 2024-06 | -9.91 | -19.28 | -9.37 | -94.55% |
2024-05-13 | 2024-03 | -16.61 | -5.75 | 10.86 | 65.38% |
2024-04-01 | 2023-12 | -49.84 | -27.48 | 22.36 | 44.86% |
2023-11-09 | 2023-09 | -47.6 | -58.47 | -10.87 | -22.84% |
2023-08-10 | 2023-06 | -88.82 | -85.62 | 3.2 | 3.60% |
2023-05-08 | 2023-03 | -79.87 | -103.83 | -23.96 | -30.00% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-07-31 | Alliance Global Partners | Upgrade | Buy | Buy |
2023-06-01 | Alliance Global Partners | Upgrade | Buy | Buy |
2021-08-30 | Alliance Global Partners | Upgrade | Buy | Buy |
2021-08-10 | Alliance Global Partners | Upgrade | Buy | Buy |
2021-02-24 | Alliance Global Partners | Upgrade | Buy | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2020-08-12 | BAGGER RICHARD H | Director | 10.00K | Purchase |
2020-08-19 | BELL MARGARET SMITH | Director | 5.39K | Purchase |
2021-05-24 | GOODMAN DANIEL WINTNER M.D. | Director | 5.00K | Purchase |
2022-06-28 | LEDERMAN SETH | Chief Executive Officer | 0.00 | Purchase |
2018-06-24 | MARIO ERNEST B | Director | 0.00 | Purchase |
2018-06-13 | MORRIS JESSICA EDGAR | Chief Operating Officer | 1.64K | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 398.75K | 630.03K | 2.24% |
2023-06-29 | Renaissance Technologies, LLC | 211.42K | 334.05K | 1.19% |
2023-06-29 | Geode Capital Management, LLC | 85.37K | 134.88K | 0.48% |
2023-06-29 | Acadian Asset Management. LLC | 68.74K | 108.61K | 0.39% |
2023-06-29 | Blackrock Inc. | 48.34K | 76.38K | 0.27% |
2023-06-29 | Raymond James & Associates, Inc. | 44.36K | 70.10K | 0.25% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 297.30K | 469.74K | 1.67% |
2023-06-29 | Vanguard Extended Market Index Fund | 100.84K | 159.33K | 0.57% |
2023-05-30 | Fidelity Extended Market Index Fund | 49.98K | 89.47K | 0.28% |
2023-05-30 | Fidelity Total Market Index Fund | 13.51K | 24.18K | 0.08% |
2023-05-30 | Fidelity Series Total Market Index Fund | 9.14K | 16.35K | 0.05% |
2023-08-30 | iShares Core S&P Total U.S. Stock Market ETF | 6.31K | 6.10K | 0.04% |
Split | Date |
---|---|
1 : 32 | 2024-06-10 |
4 : 25 | 2023-05-10 |
1 : 32 | 2022-05-17 |
1 : 10 | 2019-11-01 |
1 : 10 | 2018-11-28 |
1 : 10 | 2017-03-17 |
-
$TNXP FDA approval!! Big news
This company have more potential of other drugs in pipeline! Loading up -
$TNXP
I keep averaging down thank you!!!! Haha -
-
-
-
-
-
-
-
-
-
-
- Hope your MFs loaded up:
New to The Street T.V. again, tonight, Monday, February 14, 2022, airs the CEO at Tonix Pharmaceuticals, Inc. (NASDAQ: TNXP), Dr. Seth Lederman, M.D.’s interview with T.V. Anchor Jane King. Dr. Lederman gives the New to The Street T.V. audience an update about Tonix Pharmaceuticals, Inc.’s Covid-19 vaccine, antiviral pharmaceutical, and “Long” Covid-19 novel treatments and products. Currently, in the market, there are three (3) types of treatments in the fight against Covid-19: mRNA vaccines, antiviral therapies, and monoclonal antibodies. Seth gives a comparison and talks about the limitations of each available Covid-19 treatment. TNXP’s live vaccine, TNX-1800, in development, offers long-term protection beyond the currently used mRNA vaccines. Another in development therapy, the Company’s TNX-3500, an oral antiviral pharmaceutical, clinically shows about 65 times more potent than remdesivir in inhibiting Covid. Tests combining TNX-3500 and remdesivir shows a robust protective solution. TNX-3500 is an investigational new drug not yet approved for use. Seth talks about the Company’s upcoming clinical trials on its treatment for “Long Covid.” With its new 40,000+ sq. ft. location in Frederick, Maryland, a known biotech /biodefense sector area in the U.S., the facility and its personnel allow ongoing clinical trials and scientific development programs with economies of scale operational efficiencies and effectiveness. Seth sees Tonix Pharmaceutical as an innovator in the fight against Covid and other diseases
-
-
-
$TNXP
Fuck you hard shorts!!
You are the reason why this stock is $0.20!!
I hope you buy & cover @ $50 MFsssss -
- Shorts groups (like CITADEL) are in for a RUDE awakening. Office RAIDs at these facilities are HIGHLY likely, possibly even today. You cant HIDE what is showing on all your computers. Simply put, stock manipulation is a CRIME that can carry up to a 25 YEAR PRISON TERM. Being an employee or exec at one of these places does not provide IMMUNITY to CRIMINAL PROSECUTION.
-
Looking Into Tonix Pharmaceuticals's Recent Short Interest
news.google.com • -
Tonix Pharma Secures Patent, Eyes Migraine Market Growth
news.google.com • -
Taking the lead: Tonix Pharmaceuticals Holding Corp (TNXP)
news.google.com • -
Examining Tonix Pharmaceuticals Holding Corp (TNXP) stock is warranted
news.google.com • -
Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering
globenewswire.com • -
Tonix Pharmaceuticals Announces Proposed Public Offering
globenewswire.com • -
Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering
globenewswire.com • -
Why Is Tonix Pharmaceuticals (TNXP) Stock Down 33% Today?
investorplace.com •